Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › AI-based Immunotherapy for Ovarian, Head and Neck Cancers Evaluated in Two Phase I Trials

AI-based Immunotherapy for Ovarian, Head and Neck Cancers Evaluated in Two Phase I Trials

Jan 07, 2020
|
staff reporter

NEW YORK – Transgene and NEC Corporation announced Monday that they have advanced Transgene's immunotherapy vaccine TG4050 into two Phase I trials for patients with human papillomavirus-negative, squamous cell head and neck cancer who are at high risk of relapse after surgery, and ovarian cancer patients who have received first-line therapy after surgery. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Aug
24
Featured Webinar

Utility of Novel RNA-Based Tools in Oncology Drug Development

Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Sep
10
Featured Webinar

Development of RNA-Based Predictive Response Signatures as Companion Diagnostics

Sponsored by
Genecentric

This webinar, Part 2 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will focus on the development of RNA-based companion diagnostics for oncology.

What's Popular?

In Drug Discovery & Development

  1. T-Cure Bioscience, NHLBI Collaborate to Advance Targeted T-Cell Receptor Therapy

  2. Salarius Pharmaceuticals Expanding Phase I/II Seclidemstat Study Beyond Ewing Sarcomas

  3. Merus, Elevation Oncology Advance Drug Candidates Targeting NRG1 Fusion-Positive Cancers

    Premium

  4. Repare Therapeutics Doses First Patient in Phase I/II Trial of ATR Inhibitor RP-3500

  5. Bristol Myers Squibb, Bluebird Bio Submit Application to FDA for Multiple Myeloma CAR T-Cell Therapy

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.